KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$8.85
+2.08%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$8.73
From 52W high−4.94%
Volume178113.00
Market cap$510.74M
P/E (TTM)23.1x
P/S (TTM)2.7x
Div yield4.04%
Key dataSep 18, 2026
Open
$8.73
From 52W high
−4.94%
Volume
178113.00
Market cap
$510.74M
ValuationView details →
P/E (Fwd)
17.8x
EV/EBITDA
10.8x
P/E (TTM)
23.1x
RSI (14)
65.4
MomentumView details →
1D Return
+2.08%
YTD Return
+25.28%
SummaryUpdated Jun 1, 2026
Kamada Ltd. (NASDAQ:KMDA) is an Israeli biopharmaceutical company founded in 1990 and headquartered in Rehovot, Israel. The company went public on NASDAQ in 2013 and has transformed from a single-product dependency into a diversified plasma-derived therapeutics company. Kamada specializes in developing, manufacturing, and commercializing plasma-derived protein therapeutics, primarily targeting rare diseases and immune-related conditions. The company operates through two main business segments: Proprietary Products and Distribution, with a growing focus on the U.S. market which now represents approximately 60-70% of its revenues.
Similar companies
Latest newsMore news →
Kamada Ltd. announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel.10d agoKamada Ltd. obtained a tax ruling from the Israel Tax Authority regarding its previously announced cash dividend of $0.17 per share, totaling approximately $9.8 million, to be paid on September 17, 2026.17d agoKamada declared a cash dividend of $0.17 per share, to be paid consistent with its cash dividend policy, alongside reporting record-high revenue and profitability for the first six months of 2026.34d ago